Incredulous, page-53

Hey Supertramp..

I agree with you..

It helped bms with their drug also, but for someone to spend 6 or 700 million on a drug that may or may not work with what they have to offer, is a whole different ballgame to someone who is involved in clinical trials with them and has runs on the board..

A company that has never trialed cavatak with their drug in my opinion won’t be spending the cash on Viralytics..

There are still options for a second offer.. but the devil you know are the options imho..